September 1991
Volume 32, Issue 10
Free
Articles  |   September 1991
Promotion of murine orthotopic corneal allograft survival by systemic administration of anti-CD4 monoclonal antibody.
Author Affiliations
  • Y G He
    Department of Ophthalmology, University of Texas Southwestern Medical Center 75235.
  • J Ross
    Department of Ophthalmology, University of Texas Southwestern Medical Center 75235.
  • J Y Niederkorn
    Department of Ophthalmology, University of Texas Southwestern Medical Center 75235.
Investigative Ophthalmology & Visual Science September 1991, Vol.32, 2723-2728. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y G He, J Ross, J Y Niederkorn; Promotion of murine orthotopic corneal allograft survival by systemic administration of anti-CD4 monoclonal antibody.. Invest. Ophthalmol. Vis. Sci. 1991;32(10):2723-2728.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

A mouse model of orthotopic corneal allograft rejection was used to examine the efficacy of anti-CD4 and anti-CD8 monoclonal antibodies in preventing immunologic rejection of corneal allografts. Although it is believed by many that corneal graft rejection is mediated, at least in part, by CD8-positive cytotoxic T-lymphocytes, systemic administration of anti-CD8 antibody did not reduce the rejection rate of corneal allografts that differed from the host at the entire major histocompatibility complex. By contrast, systemic administration of anti-CD4 monoclonal antibody reduced the rejection rate from 83% (untreated controls) to 33%. Fluorocytometric analysis of residual lymphoid populations showed that neither monoclonal antibody eliminated the inappropriate subset of T-cells in antibody-treated animals. In vitro cell-mediated cytotoxicity assays showed that both antibodies eliminated allospecific cytotoxic T-lymphocyte populations; however, only anti-CD4 antibody promoted graft survival. Thus, these results indicate that anti-CD4 monoclonal antibody is a powerful immunosuppressive agent for promoting corneal graft survival and that CD8-positive T-cells alone do not cause rejection of corneal allografts.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×